Friday, 24 April 2026
  
Login

Australia's most trusted
source of pharma news

Friday, 24 April 2026
News

RWE feud goes legal

Posted 24 April 2026 PM

Nubeqa developer Bayer has fallen short in a bid to block Johnson & Johnson’s survival claims for Erleada in the US.

Both brands belong to a class of drugs known as androgen receptor inhibitors. Erleada, marketed under the brand name Erlyand in Australia, was listed on the PBS in May 2022 for non-metastatic hormone sensitive prostate cancer (nmHSPC) before being expanded on the scheme in June 2023 for metastatic hormone-sensitive prostate cancer (mHSPC). Bayer’s Nubeqa is listed on the scheme for the same indications.

To see the whole article, please login

Popular

Aussie pharma naughty or nice?
One of industry's best moves on
Final contender in MA Board race
PBS a lever for medicine supply?
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home